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Abstract
Background: This paper summarizes the results of a group effort to bring together the worldwide available data
on patients who are either homozygotes or compound heterozygotes for mutations in MAT1A. MAT1A encodes the
subunit that forms two methionine adenosyltransferase isoenzymes, tetrameric MAT I and dimeric MAT III, that
catalyze the conversion of methionine and ATP to S-adenosylmethionine (AdoMet). Subnormal MAT I/III activity
leads to hypermethioninemia. Individuals, with hypermethioninemia due to one of the MAT1A mutations that in
heterozygotes cause relatively mild and clinically benign hypermethioninemia are currently often being flagged in
screening programs measuring methionine elevation to identify newborns with defective cystathionine β-synthase
activity. Homozygotes or compound heterozygotes for MAT1A mutations are less frequent. Some but not all, such
individuals have manifested demyelination or other CNS abnormalities.
Purpose of the study: The goals of the present effort have been to determine the frequency of such abnormalities,
to find how best to predict whether they will occur, and to evaluate the outcomes of the variety of treatment
regimens that have been used. Data have been gathered for 64 patients, of whom 32 have some evidence of
CNS abnormalities (based mainly on MRI findings), and 32 do not have such evidence.
Results and Discussion: The results show that mean plasma methionine concentrations provide the best
indication of the group into which a given patient will fall: those with means of 800 μM or higher usually have
evidence of CNS abnormalities, whereas those with lower means usually do not. Data are reported for individual
patients for MAT1A genotypes, plasma methionine, total homocysteine (tHcy), and AdoMet concentrations, liver
function studies, results of 15 pregnancies, and the outcomes of dietary methionine restriction and/or AdoMet
supplementation. Possible pathophysiological mechanisms that might contribute to CNS damage are discussed, and
tentative suggestions are put forth as to optimal management.
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Background
More than sixty years ago Giulio Cantoni described an
enzyme that utilized methionine and ATP to form a
then novel product needed for transmethylation reac-
tions [1], which he soon identified as S-adenosyl-
methionine (AdoMet) [2]. Since then, AdoMet has
turned out to be among the most versatile compounds
in all of biology. In humans AdoMet is used by as many
as 200 or more methyltransferases [3]; after decarboxyl-
ation, as a source of aminopropyl groups in polyamine
biosynthesis [4]; possibly as a source of other moieties
[5]; and as a regulator of sulfur amino acid metabolism
[6] and liver function [7]. Evidence has been presented
that humans have a few enzymes that, as members of
the group of more than 2800 proteins that comprise
the biologically widespread radical SAM superfamily,
use a 5′-deoxyadenosyl radical derived from AdoMet
[8]. The structure of methionine adenosyltransferase
(MAT)(E.C. 2.5.1.6), the enzyme that synthesizes AdoMet
has been highly conserved during evolution: in a study of
292 MAT genes occurring in bacteria and eukaryota there
was perfect conservation of active site residues, approxi-
mately 30 % of the encoded amino acids were identical in
all species [9]. Humans possess two genes encoding iso-
forms of MAT: MAT1A encodes a catalytic subunit that
forms the tetrameric and dimeric holoenzymes, MAT I
and MAT III. MAT2A encodes the catalytic subunit of
MAT II [10]. Sánchez-Pérez et al. found that each ver-
tebrate included in their study had two MAT genes that
encoded amino acid sequences with about 85 % iden-
tity, suggesting a gene duplication that occurred after
the human lineage diverged from the sea squirts (Uro-
chordata), but before divergence from the jawed verte-
brates (Teleostomi) [9], perhaps 400–500 million years
ago. MAT II is the major isozyme in non-hepatic tis-
sues and in fetal liver, whereas MAT I and III are the
major forms present in post-natal liver [10]. However,
MAT1A expression has been reported in pancreas [11]
and, more recently, in small amounts in most tissues,
including brain [12]. After the introduction of screening
newborns for methionine elevations to detect homocys-
tinuria due to cystathionine β-synthase deficiency, in-
fants were discovered in the United States [13], France
[14], and Japan [15] with elevated blood methionine but
without abnormal levels of homocystine, and MAT ac-
tivities were shown to be low in extracts of their livers
[13, 15–18], as well as in that of an adult patient found
to be hypermethioninemic when investigated because
of malodorous breath due to dimethylsulfide [19, 20].
The kinetic properties of the residual hepatic MAT ac-
tivities of these patients [16, 19] as well as the finding
that MAT activities in a variety of their non-hepatic tis-
sues were normal indicted that the defective activity was
that encoded by MAT1A [16, 17, 21]. Establishment of the
amino acid sequence encoded by MAT1A [22–24] then
opened the way to finding MAT1A mutations in most of
the patients in question [25–27]. As screening of new-
borns for methionine elevations has expanded, MAT1A
mutations are turning out to be the most common genetic
cause of newborn hypermethioninemia [28–31]. Most
such cases are heterozygous for R264H, a mutation in
which the activity of wild-type subunits is suppressed by
combination with mutant subunits [32, 33]. Several
other such dominant mutations have now been identi-
fied [31, 34, 35]. Clinically, heterozygotes for such mu-
tations have been unaffected. However, in addition, a
number of patients with homozygous or compound het-
erozygous MAT1A mutations have been found through
newborn screening [30, 31, 36–44], and although some of
these patients have been clinically unaffected, some of
them have had brain demyelination or other MRI abnor-
malities. Treatments used have included dietary methio-
nine restriction or supplementation with AdoMet, but
optimal management has not yet been clearly established.
With the aim of providing information on the criteria for
prognosis and optimal treatment of such patients we have
recently made an effort to collect as much information as
possible on the clinical status and outcomes and the meta-
bolic details of patients for whom sequencing has shown
either homozygous or compound heterozygous MAT1A
mutations, or those with hypermethioninemia and defi-
cient MAT activities. The findings are presented and dis-
cussed in this paper.
Methods
A literature search was carried out to identify patients
who had been found to be homozygotes or compound
heterozygotes for MAT1A mutations or who, although
not genotyped, had been shown to have deficient activ-
ities of hepatic MAT. Information on such patients was
taken from relevant publications and analyzed together,
whenever possible, with updated information submitted
by coauthors based on their experiences in manage-
ment of, or diagnostic studies of, the patients in ques-
tion. In addition, physicians taking care of MAT I/III
patients came known to the authors via support in the
diagnostic process or counseling on potential treatment
of these patients. Informed consent was obtained from
the patients or their parents and local ethical rules were
followed. Ethical approval was obtained from the Office
of Human Subjects Research (OHSR) at the NIH,
Bethesda, USA.
Patients were considered to have “CNS abnormality” if
their brain MRI showed abnormalities or if presence of
any neurological symptom was reported or both.
In Tables 1 and 2 the references are given of those pa-
tients that have been published before.
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Table 1 Patients without evidence of CNS abnormalities








Age < 5 m
Met range
Age≥ 5 m Met
mean ± SD
MRI (age) Citation†
G1 F 40.4 c.966T>G (p.Ile322Met) 7.8* NBS 1270 373 ± 133 Normal (22) [17, 25, 46, 58]
c.966T>G (p.Ile322Met) 21/21
G2 M 38 c.914T>C (p.Leu305Pro) 10.2* NBS 364–583 394 ± 118 — [17, 25]
c.966T>G (p.Ile322Met) 26/21
G3 F 2 c.164C>A (p.Arg55Asp) 10.91* NBS 389–1020 315 — [17, 25]
c.1070C>T (p.Pro357Leu) 26/31
G4 F 31.4 c.1068G>A (p.Arg356Gln) 17.5* NBS 42–408 146 ± 38 — [17, 26]
c.1132G>A (p.Gly378Ser) 11/0.2 402
2 M 60.1 c.539insTG (p.Thr185X) 28* Breath odor — 805 ± 106 Normal (31) [19, 20, 78]
c.539insTG (p.Thr185X)
3 F 21.5 c.539insTG (p.Thr185X) NA NBS 1870–2542 777 ± 169 Normal (6) [26, 58]
c.539insTG (p.Thr185X) 1870
10a M 25 c.595C>T (p.Arg199Cys) 11/11 NBS 496–670 520 ± 124 — [26, 58]
c.595C>T (p.Arg199Cys) 670
11a F 28.5 c.595C>T (p.Arg199Cys) 11/11 NBS 591–654 475 ± 118 — [26, 58]
c.595C>T (p.Arg199Cys) 591
14 F 6.4 c.966T>G (p.Ile322Met) 11/11 NBS 440–467 225 ± 57 — [27, 58]
c.1031A>C (p.Glu344Ala)
15b F 2.2 c.1132G>A (p.Gly378Ser) 0.2/75 NBS 383–1089 519 — [80]
c.1161G>A (p.Trp387X)
16b F 4.7 c.1132G>A (p.Gly378Ser) 0.2/75 Family — 782 ± 400 — [80]
c.1161G>A (p.Trp387X)
17 F 21.4 c.791C>T (p.Arg264Cys) 0.3/31 NBS 648 322 — [42]
c.1070C>T (p.Pro357Leu)
18 M 21.2 c.1070C>T (p.Pro357Leu) 31/31 NBS 505 325 ± 244 — [42]
c.1070C>T (p.Pro357Leu)
19 F 16.5 c.1067G>C (p.Arg356Pro) 11/31 NBS 622 175 — [34, 42]
c.1070C>T (p.Pro357Leu)
21 F 7.1 c.836G>T (p.Gly279Val) NA/2 NBS 596 436 ± 1 — [34]
c.964A>G (p.Ile322Val)
23 F 3.9 c.539insTG (p.Thr185X) NA NBS 216–1457 665 ± 160 — [38]
c.822G>C (p.Trp274Ser)
24c M 1.2 c.689T>G (p.Val230Gly) NA NBS 518–525 769 ± 112 —
c.689T>G (p.Val230Gly)
25c F 4.9 c.689T>G (p.Val230Gly) NA Family – 838 ± 18 —
c.689T>G (p.Val230Gly)
26 F 2.9 c.527T>A (p.Leu176Gln) NA NBS
57
57–200 76 ± 24 —
c.527T>A (p.Leu176Gln)
28 F 20 c.65C>T (p.Ser22Leu) 46/46 NBS — 975 ± 177 normal (20) [34, 37, 44]
c.65C>T (p.Ser22Leu)
33 U 2 c.856G>A (p.Asp286Asn) NA NBS 106–1570
del at least exons 6-8
40 F 0.4 c.1141G>A (p.Gly381Arg) 25/25 NBS 1207–2121 1673 — [34]
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Results
Summary tables
Currently data are available for 64 patients. Because a sub-
stantial portion of these patients have evidence of CNS ab-
normalities, we divided them between those without
(Table 1) (n = 32) and with evidence of CNS abnormalities
(Table 2) (n = 32). These Tables show many more import-
ant features of the patients, including their MAT1A geno-
types, their age at last report, cause of ascertainment,
plasma methionine concentrations and whether MRI’s, if
performed, were normal or abnormal. Tables 3 and 4
present the brief clinical histories of the patients with pos-
sible CNS abnormalities, the interventions used (if any),
and the MRI findings at specified ages.
Possible criteria to distinguish between those with and
without CNS problem (Tables 1 and 2)
MAT1A genotypes
MAT1A genotypes are not clearly predictive. Patients
with homozygous truncating mutations with presumably
no residual MAT I/III activity are found among those
without CNS problems (patients 2 and 3), and most of
the patients with CNS problems have only missense mu-
tations which, when expressed in E. coli, had some re-
sidual MAT activities.
Plasma methionine concentrations
For untreated patients for whom more than one value
for plasma methionine during the first few months of life
were available, values often varied relatively widely
(Fig. 1). After that time methionine concentrations
tended to be less variable for a given patient. As shown
in Fig. 2, on normal diets mean methionine values for
patients with evidence of CNS abnormalities were usu-
ally higher than were those for patients without evidence
of such abnormalities. Those with mean values above
800 μM almost always have CNS abnormalities, whereas
those with means less than 800 μM usually do not. In
the total group (all ages) three patients with CNS abnor-
malities were below 800 μM and six patients without
Table 1 Patients without evidence of CNS abnormalities (Continued)
c.1141G>A (p.Gly381Arg)




48 M 5.4 c.446T>A (p.Met64Lys) NA NBS
134
134–1567 — Normal (yearly,




49 F 0.3 c.110T>C (p.Ile37Thr) NA NBS
407
403–408 — — [31]
c.271G>A (p.Gly91Ser)
52 M 0.54 c.823G>C (p.Gly275Arg) NA NBS 949–1074 — normal (0.5)
c.823G>C (p.Gly275Arg)
53 F 2.3 c.862A>G (p.Thr288Ala) NA NBS 121–484 495 ± 275 [30]
c.862A>G (p.Thr288Ala)
54 F 2.0 c.1064T>G (p.Leu355Arg) NA NBS
185
185–410 — — [30]
c.1064T>G (p.Leu355Arg)
57 U 3.5 c.169+1G>A NA NBS
860
860–1130 918 ± 84 —
c.169+1G>A
58d M 12.3 not sequenced 22.7* NBS 268–1005 369 ± 237 — [15]
268
59d M 13.7 not sequenced 23.1* Family — 350 ± 50 — [15]
64 M 4.5 m c.596G>A (p.Arg199His) NA NBS 118–208 — —
c.596G>A (p.Arg199His)
†Patients are assigned the same identifiers as were used when they were first described in the following papers: Patients G1, G2, G3, G4 [17]; Patients 3, 10, 11
[58]; Patients 17, 18, 19; numbers 1, 2 and 5 [42]; Patient 28: patient 1 [44]; Patients 53, 54: patients 14 and 18 [30]
*Activity based on assay of hepatic extract; others based on activity of mutant recombinant forms expressed in E coli [34]
aSibs are designated by the same superscript
†Cont. indicates that methionine restriction or AdoMet supplementation was continuing at last report
NBS: Newborn screening
NA: not available
Met: methionine concentration in umol/L
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CNS abnormalies were above 800 μM. The respective
means (± SD) for these two groups were 1073 μM± 233
and 485 μM± 276.
Plasma AdoMet concentrations
Data for the available concentrations of plasma AdoMet
at age ≥ 5 months are shown in Fig. 3. Although, as
already shown in Fig. 2, most patients with evidence of
CNS abnormalities have higher plasma methionines,
there is no trend for a difference in the AdoMet con-
centrations between those with and without such evi-
dence, and the mean values (± SD) were, respectively
84 nM ± 19 and 72 nM ± 13.
Plasma total homocysteine (tHcy) values
Figure 4 shows values of plasma methionine and tHcy
for the individual samples in which both of these were
assayed. To provide more indication of the range of
values encountered at young ages, points are plotted for
samples drawn either before (circles) or after (triangles)
age 5 months. As plasma methionine rises, tHcy tends to
rise also, so that patients with evidence of CNS abnormal-
ities tend to have higher levels of tHcy. However at the
higher methionine concentrations there is no apparent
difference in the tHcy values between those with and
without CNS abnormalities, indicating the response to
methionine elevation is about the same in the two groups.
Plasma cystathionine values
Among the few patients for whom sensitive serial assays
of cystathionine were performed at early ages cystathio-
nines were mildly elevated at 16 days, 21 days, 38 days
and 1.5 months with values, respectively of 776, 1196,
1280, and 1001 nM (adult reference range 44–342 nM).
Values had fallen to 566 and 670 nM by 11 months and
thereafter were, at most, only slightly above the refer-
ence range (data not shown in Tables).
Liver function studies
The results of liver function studies are available for
16/32 patients without and 14/32 of those with evi-
dence of CNS abnormalities. Included are assays (in
some patient multiple times) of ALT and AST, total bili-
rubin, alkaline phosphatase, albumin, total plasma pro-
tein, and gamma glutamyltranspeptidase. No instances
of hepatic malfunction have been detected by these
studies (data not shown in Tables).
Pregnancy outcomes
Information is available on 15 pregnancies among six of
the present patients:
Patient G1 had four pregnancies. Because the patient’s
plasma choline was below the reference range, and
because brain damage occurs in fetuses of experimental
animal mothers fed low choline diets [45], she was advised
after gestation week 17 in three of these pregnancies
to ingest two eggs daily to provide about 630 mg
choline/day. Three normal children were born who
have continued to develop normally mentally and
physically. In the fourth pregnancy there were no overt
complications but sonography at ten weeks disclosed
fetal arrest and the pregnancy was terminated two
weeks later [46].
Patient G4 took 600 mg choline/day during most of her
initial pregnancy and produced a normal baby. During
a second pregnancy she took 2 eggs/day from 18 weeks
gestation, and then changed to choline capsules, 600 mg/d
during the remainder of the pregnancy. A normal child
was born who continued to be normal at last investigation
at age 6 months.
Patient 3 had been temporarily lost to follow-up, but
was relocated and found to have produced a normal baby
without any specific treatment due to her MAT I/III
deficiency.
Patient 5 had also been lost to follow-up after childhood,
but was found again when she produced a baby that was
flagged during NBS for elevated methionine that turned
out to be transient [47].
Patient 4 produced a normal baby after a pregnancy
during which she continued her usual dose of AdoMet,
200 mg bid.
Patient 56 was ascertained at age 38 with elevated
methionine and tHcy because she had given birth to
two children with transient hypermethioninemia (NBS
methionines of 552 and 554 μM, falling to 94 μM on
day 5 or 42 μM on day 4 of life). Her history revealed
that she had had six pregnancies with one lost at 4 weeks,




Because of the mild elevations of tHcy often encoun-
tered in MAT1A deficient patients, 6 of the 32 with-
out and 7 of the 32 with evidence of CNS abnormalities
(data not shown in Tables) have been given brief tri-
als of high doses of vitamin B6. In almost all cases
there were no significant effects. One patient (#36)
did experience a marked decrease in plasma methio-
nine during an initial period of B6 treatment, but that
response did not occur during a second trial nor in
her identical twin sister (#37). In addition, even some
adverse events were reported in patients using high
doses of B6 [48]. One MAT I/III deficient infant (#7)
became apneic and required respiratory support shortly
after starting a dose of pyridoxine of 500 mg/day [49], and
Tada et al. reported that pyridoxine treatment may have
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Table 2 Patients with evidence of CNS abnormalities
Patient Sex Age last
report years




Age < 5 m
Met range





1 M 24.2 c.113G>A (p.Ser38Asp) 8* NBS 670–1237 1030 Abnormal (20.7) [14, 16, 27, 58]
c.255delCA (p.Tyr92X) 0/NA 670
4 F 32 c.827insG (p.Lys351X) NA NBS — 600–1400 Abnormal (11) [26, 64]
c.827insG (p.Lys351X) Normal (12)
5 F 26.1 c.791C>T (p.Arg264Cys) 0.3/23 NBS 201–1740 909 ± 272 Normal (13) [27, 47, 58]
c.1006G>A (p.Gly336Arg) 201 IQ 84 (14)
Learning disability
(14)
7 M 17.8 c.292G>A (splicing) NA NBS 1226–1664 1428 ± 320 Normal (0.75) [27, 58]
c.292G>A (splicing) 1226 Abnormal (4.2)
Abnormal (11)
8 F 13.6 c.1043delTG (p.His350X) NA Dystonia — 1157 ± 445 Abnormal (9) [26, 58]
c.1043delTG (p.His350X)
9 M 8.7 c.595C>T (p.Arg199Cys) 11/NA NBS 966–1467 879 ± 140 Normal (6) [26, 58]
c.539insTG (p.Thr185X) IQ 65 (6)
13 F 6.2 c.595C>T (p.Arg199Cys) 11/11 NBS 635–738 485 ± 49 Abnormal (8) [26, 58]
c.595C>T (p.Arg199Cys) Slow at school (16)
20 F 10.8 c.205G>A (p.Gly69Ser) 109/NA NBS — 1400 Abnormal (10) [42]
c.1188G>T (p.X396YfsX464) 1560
22 F 7.5 c.874C>T (p.Arg292Cys) 14/NA NBS — 1005–1676 Abnormal (2.9) [38, 81]
c.1067G>T (p.Arg356Leu) 395 Normal (6.4)
IQ 60 (5.4)
29 M 14.2 c.125T>C (p.Leu42Pro) 10/10 NBS 121–1541 1437 ± 498 Abnormal (13) [34, 37, 44]
c.125T>C (p.Leu42Pro) 121 IQ 73 (13)
30e M 7.0 c.274T>C (p.Tyr92His) 104/11 NBS 740 830 ± 368 IQ 121 (3) [34, 36, 41]
c.1067G>C (p.Arg356Pro) Abnormal (3.8)
Better (5.5)
Normal (7)
31e M 3 c.274T>C (p.Tyr92His) 104/11 NBS 820–2250 900–1140 Abnormal (0.8) [34, 41]
c.1067G>C (p.Arg356Pro) Abnormal (3)
32 M 9.4 c.433G>A (p.Glu145Lys) NA/14 NBS 1740–1870 740–1150 Abnormal (5) [34, 43]
c.874C>T (p.Arg292Cys) Abnormal (9.4)
IQ 108 (9.4)
34 M 0.63 c.1068G>A (p.Arg356Trp) 4/4 NA 1846–3500 — Severe retarded [34]
c.1068G>A (p.Arg356Trp)
35 F 2.8 c.292G>A (splicing) NA/11 NBS 1544–1685 1159 Abnormal (1.2) [26]
c.595C>T (p.Arg199Cys) Better (1.8)
36f F 1.3 c.539insTG (p.Thr185X) NA/20 NBS† 1400 1549 Normal (2.3) [34]
c.890C>A (p.Ala297Asp) 1400 Delayed
development (2.3)




38g F 13 c.896G>A (p.Arg299His) 13/13 Neuro-logical – 1016 ± 549 Abnormal (12.8) [34]
c.896G>A (p.Arg299His)
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worsened the MRI and neurological abnormalities in their
patient (#30) [36]. Taken together, high doses of vitamin
B6 should not be used in patients with MAT I/III
deficiency.
Dietary methionine restriction
Methionine restriction has been used for 8/32 patients
without CNS abnormalities and 16/32 patients with CNS
abnormalities, starting at various ages and continued for a
Table 2 Patients with evidence of CNS abnormalities (Continued)
Delayed
development (3)
39g M 9.8 c.896G>A (p.Arg299His) 13/13 Family — 1000 ± 192 Abnormal (5.2) [34]
c.896G>A (p.Arg299His) Delayed in
learning (10.5)
41 F 7.6 p.MAT1Adel NA NBS 192–1608 — Abnormal (0.2)
p.MAT1Adel 192 Normal (7.1)
42 M 1.9 c.607delATC (p.Ile203del) NA NBS 148–1490 1144 ± 143 Abnormal (1.2)
c.607delATC (p.Ile203del) 148 Speech delay (1.5)
43 M 4.2 c.934C>T (p.Arg312Trp) NA NBS 460–1437 1120 Abnormal (3.8)
c.934C>T (p.Arg312Trp) IQ 78 (3.3)
45 F 4.5 c.292G>C (p.Gly98Arg,
splicing?)




46 F 34 c.274T>C (p.Tyr92His) 8.3* NBS 402–1340 1326 ± 159 Abnormal (30) [15]
c.1067G>C (p.Arg356Pro) 104/11 IQ 99 (9)
47 F 17 c.1033insG (p.Lys351X) NA Unknown — — Abnormal (9)
c.1033insG (p.Lys351X) Almost normal (17)
50h F 4.9 c.896G>A (p.Arg299His) NA Neuro-logical — 878 ± 136 Abnormal (3.3) [34]
c.896G>A (p.Arg299His)




56 F 39 c.896G>A (p.Arg299His) NA Hi met baby — 1233 ± 513 Neurological
abnormality
c.896G>A (p.Arg299His)
60 F 6.1 c.895C>T (p.Arg299Cys) 20/20 NBS 800–1067 1013 ± 283 Abnormal (1.4) [34, 40]
c.895C>T (p.Arg299Cys) Mild delay (5.6)
61 F 1.0 c.688G>A (p.Val230Met) NA /11 NBS 205–328 84 ± 34 Abnormal (4.5) [82]
c.1067G>C (p.Arg356Pro) Neurologic normal
(5.5)
62 M 4.3 c.169G>A (p.Glu57Lys,
splicing?)





63 M 2.9 c.169-2A>c.734_735delAG
(p.Gln245Profs*20)G
NA/0.3 NBS 938–1271 905 ± 99 Abnormal (0.8)
c.791C>T (p.Arg264Cys) Worsen (1.5)
†Patients are assigned the same identifiers as were used when they were first described in the following papers: patient 1 [14, 16]; patients 5, 7, 8, 9 and 13 [58];
patient 20: 14 [42]; patient 22 [38]; patient 29: patient 2 [44]; patient 30 [36]; patient 31 [41]; patient 32 [43]; patient 46: case 2 [15], and patient 61 [82]
*Activity based on assay of hepatic extract; others based on activity of mutant recombinant forms expressed in E coli [34]
a Sibs are designated by the same superscript
†Cont. indicates that methionine restriction or AdoMet supplementation was continuing at last report
NBS: Newborn screening
NA: not available
Met: methionine concentration in umol/L
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Table 3 Outcomes for treated patients
Patient # Diet Time period Met μM MRI Clinical
Start years End years Mean ± SD (N)
Patients without evidence of CNS problems who had periods of dietary methionine restriction
3 Normal Birth 4.5 m 2262 ± 350 (3)
Restricted 4.5 m 3.4 y 462 ± 70 (5)
Normal 3.4 y 21.5 y 777 ± 169 (8) Normal (6 y) Normal (21.5 y)
17 Normal Birth 0.8 m 648 (1)
Restricted 0.8 m 21.4 y 282 ± 42 (3)
Normal 21.4 y 22 y 314 (1) n.d. Normal (21.4 y)
18 Normal Birth 1 m 305 (1)
Restricted 1 m 14 y 135 ± 40 (3)
Normal 14 y 21.2 y 327 ± 241 (2) n.d. Normal (21.2 y)
19 Normal Birth 1 m 622 (1)
Restricted 1 m 16.4 y 156 ± 36 (5)
Normal 16.4 y 16.5 y 175 (1) n.d. Normal (16.5 y)
21 Normal Birth 0.4 m 596 (1)
Restricted 0.4 m 5.8 y 282 ± 95 (6)
Normal 5.8 y 7.1 y 436 ± 1 (2) n.d. Normal (7.1 y)
48 Normal Birth 1 m 643 ± 646 (3)
Restricted 1 m 5.4 y 545 ± 118 (50) n.d. Normal (5.4 y)
53 Normal Birth 4.3 m 303 ± 257 (2)
Normal 5.2 m 1.2 y 495 ± 275 (4)
Restricted 1.2 y 2.3 y 266 ± 96 (3) n.d. Normal (2.3 y)
58 Birth 1 m 783 ± 337 (3)
Restricted 1 m 6 m 134–268 (2)
Normal 6 m 6.5 m 536 (1)
Restricted 6.5 m 6 y 67–268 (2)
Normal 6 y 36 y 263 ± 83 (7) n.d. No problems (6 y)
Patients with evidence of CNS problems who had periods of dietary methionine restriction
1 Normal Birth 2 m 954 ± 401 (2)
Restricted 2 m 24 y 100–600 (2) Abnormal (20.7 y) Normal intelligence (24 y)
5 Normal Birth 3 m 1345 ± 661 (5)
Restricted 6 m 2.5 y 899 ± 129 (4) Considered slow
Normal 2.5 y 26.1 y 909 ± 272 (3) Normal (13 y) Wechsler Intelligence Scale verbal 88,
performance 84 (7.5 y)
9 Normal Birth 1 m 1217 ± 354 (2)
Restricted 1 m 1.2 y 220 ± 176 (10)
Normal 1.2 y 8.7 y 879 ± 140 (5) Normal (6 y) IQ 65 (1st percentile) (6 y)
13 Normal Birth 1.3 m 697 ± 87 (2)
Restricted 1.7 m 10 m 193 ± 83 (4)
Normal 10 m 10 y 485 ± 49 (4) Abnormal (8 y) Slow at school (16 y)
20 Normal Birth 1.5 m 1528 ± 85 (4) Abnormal (0.1 y)
Restricted 1.5 m 6.6 y 684 ± 234 (14) Normal (4.9 y) Normal (5.4 y)
Normal 6.6 y 10.5 y 1298 ± 112 (5) Abnormal (10 y)
Chien et al. Orphanet Journal of Rare Diseases  (2015) 10:99 Page 8 of 21
Table 3 Outcomes for treated patients (Continued)
Restricted 10.5 y 10.8 y 1180 (1)
30 Normal Birth 0.6 m 740
Restricted + betaine 0.6 m 2.5 y 400–1580
Restricted + betaine + B6 2.5 y 3.9 y 1080–1370 Abnormal (3.8 y) IQ 121 (3.5 y)
Normal 3.9 y 9 y 1050 Improved (5 y) better (7 y)
31 Normal Birth 3 m
Restricted 3 m 1.8 y Abnormal (0.8y) Development normal
Abnormal (3 y)
32 Normal Birth NA 1805 ± 92 (2)
Restricted NA 5.2 Y 740–1150 Abnormal (5 Y)
Normal 5.2 Y 9.4 Y NA Abnormal (9.4 y) IQ 108 (9.4 y); neurologically normal
43 Normal Birth 4 m 949 ± 691 (2)
Normal 4 m 6 m 1145
Restricted 9.6 m 3.2 y 928 ± 74 (8)
Normal 3.2 y 3.8 y 1120 (1) Abnormal (3.8 y) Performance IQ 78; reasoning 57 (3.3 y)
Restricted 4 y 4.2 y 994 (1)
46 Normal Birth 1.5 m 1027 ± 542 (3)
Restricted 1.5 m 4 y 332 ± 341 (28)
Normal 4 y 34 y 1326 ± 159 (29) Abnormal (30 y) Physical and mental development
normal (34 y)
61 Normal Birth 735 Normal
Restricted + betaine 2 w 3.59 y 700–1100 Abnormal (3.5 and 4.5 y) Normal
62 Normal Birth < 5 m 461 (1)
Normal 1 y 2.1 y 860 ± 424 (3) Developmental delay; autistic action (2.2 y)
Restricted 2.1 y 2.4 y 7 (1) Normal (2.3 y) Improved (2.4 y)
Normal 2.4 y 4.3 y 741 ± 71 (2) IQ = 108 (3.3 y)
Normal (4.3 y)
63 Normal Birth 1 m 1105 ± 235 (2)
Restricted 1 m 1 y 570 (1) Abnormal (0.8 y)
Normal 1 y 2.9 y 905 ± 99 (3) Worse (1.5 y) No neurological signs (2.9 y)
Patients treated with AdoMet supplementation only
4 Normal Birth 11 y 600–1400 (2) Abnormal (11 y) Headaches, nystagmus, dysdiadochokinesis,
increased tendon reflexes (11 y)
AdoMet, 400 mg bid 11 y 12 y Normal (12 y)
AdoMet, 200 mg bid 17 y 32 y 565 ± 139 (17) Normal baby daughter (30 y)
22 Normal Birth 4.7 y 1005–1676 (2) Abnormal (4.7 y) IQ 49 (3.7 y)
AdoMet, 400–800 mg bid 4.7 7.4 y 1528 (1) Normal (6.4 y) IQ improved to 69 (5.4y); awake EEG
markedly improved (6.3 y); IQ 64 (7.4 y)
35 Normal Birth 3 m 1620 ± 107 (2)
? 3 m 1.2 y 1159 (1) Abnormal (1.2 y)
AdoMet 100–200 mg bid 1.3 y 1.8 y 759 ± 278 (2) Improved overall (1.8 y)
50 Normal Birth <4.3 y 878 ± 136 (3) Abnormal (4.3 y)
AdoMet, 200 mg bid 4.4 y 4.5 y
AdoMet, 400 mg bid 4.5 y 4.9 y Behavior considerably improved
51 Normal Birth 3.3 y 641 ± 74 (2) Abnormal
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range of times. Details for each such patient are re-
ported in Table 3 (see supplementary data), together
with the mean plasma methionine concentrations be-
fore, during, and after restriction and very brief comments
describing if and when MRI or clinical abnormalities were
observed. For each patient with evidence of CNS abnor-
malities more detailed clinical histories and the reports
of MRI findings are presented in Table 4 (see supplemen-
tary data). The pros and cons of using dietary restric-
tion are described in more detail in the “Discussion”
[sections 4.4.1 and 4.4.2].
AdoMet supplementation
AdoMet supplementation has been used for nine pa-
tients, each of whom had abnormal CNS findings.
AdoMet was given during periods of methionine re-
striction in four of these nine patients. Summaries of
these trials are listed in Table 3 with more details in
Table 4. AdoMet supplementation is also discussed in
the “Discussion” [section 5.2.1].
Discussion
Sufficient information has been gathered during the
present survey to permit discussion of several important
questions about MAT I/III deficiency:
Diagnosis
The possibility of MAT I/III deficiency usually arises
with the finding of elevated plasma methionine without
the marked elevations of tHcy that occur in CBS defi-
ciency [50]. However, uncertainty may arise because, as
shown in Fig. 4, MAT I/III deficient patients tend to
have mild elevations of tHcy as their methionine levels
rise. Assay of plasma AdoMet then becomes a useful
next step, since plasma AdoMet is elevated in CBS defi-
ciency (median 488 nM; 25–75 percentile, 155–868) [51],
but is usually not elevated in samples from MAT I/III defi-
cient individuals drawn at age of more that 3–4 months
(Fig. 3). However, the few MAT I/III deficient patients
among those under discussion who had early samples
assayed for AdoMet often had very mild elevations of
AdoMet (as high as 152 nM), and similar or slightly
higher elevations (up to 220 nM) have been found in
early samples from patients with one of the MAT1A
mutations (e.g., R264H) that cause slight to moderate
hypermethioninemia in heterozygotes. These rises do
not persist beyond about age three months, and may
perhaps be due to incomplete turning off of the expres-
sion of MAT II that occurs after birth. Thus, when in-
vestigating a child who at an early age has elevated
methionine and, at most, slight elevations of tHcy and
Table 3 Outcomes for treated patients (Continued)
AdoMet, 400 mg bid 4.7 y Not available
Patients who had periods of dietary restriction and AdoMet supplementation
7 Normal Birth 0.5 m 1445 ± 310 (2)
Restricted 1 m 4 m 516 ± 192 (5)
Normal 4 m 6 m 1138 (1)
Restricted 6 m 9 m 1451 (1) Normal (9 m) Developmental delays
Normal 9 m 14 y 1457 ± 322 (10) Abnormal (4.2 y) Impaired function; fine tremor
AdoMet, 200 mg/d 14.1 y Brief trial of AdoMet . Attempts to assess
efficacy failed due to loss of follow-up.
The supplement was stopped by the
family who considered there had not
been noticeable clinical improvement.
34 Normal Birth 5.5 m
Restricted + AdoMet 5.5 m 8.3m Improved clinically on combined methionine
restriction and AdoMet supplemenation,
but details not available.
41 Normal Birth 0.2 y 919 ± 795 (4)
Restricted 0.2 y 6.7 y 313 ± 226 (9) Abnormal (0.2 y)
Restricted + AdoMet 6.7 y 7.6 y 455 ± 104 (5) Normal (7.1 y) Appetite improved (7.1 y)
45 Normal Birth 1.8 m 760 ± 357 (2)
Normal 1.8 m 4.1 y 901 ± 163 (4) Abnormal (4 y) Physical and neurologic examinations
normal (4 y)
Restricted + AdoMet 4.1 4.7 468 ± 120 (4) Improved (4.5 y)
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AdoMet, further evidence as to whether that child is a
heterozygote, homozygote, or compound heterozygote
for MAT1A mutation(s), may be obtained by assaying
plasma methionine in both parents. If the child is a het-
erozygote for a dominant mutation one parent will also
have at least a minimal elevation of plasma methionine.
Strong evidence indicates that such heterozygotes will
be clinically unaffected [30, 31]. If neither parent is
hypermethioninemic, to pin down the diagnosis the
MAT1A gene may be sequenced so that further moni-
toring and/or trials of therapy can take place if the
child turns out to be a homozygote or compound het-
erozygote for MAT1A mutation(s).
Another finding is elevated cystathionine in samples of
patients of young age, which may even be used as an
additional marker to distinguish MATI/III deficiency
from CBS deficiency [52]. Again, this elevation is transi-
ent and may probably be attributed to incomplete ex-
pression of cystathionine gamma-lyase, which activity is
not expressed in fetal liver [53].
Liver function and hepatocellular carcinoma
MAT1A knocked out mice develop oxidative stress and
nonalcoholic steatohepatitis by 8 months [54] and, a high
incidence of hepatocellular carcinoma by 18 months [55].
Liver histology was studied in a few early MAT I/III-de-
ficient patients who had liver biopsies performed to
assay MAT activity before MAT1A genotyping became
available. Light microscopy was usually normal (patients
G1, G3 [17]; #2 [19]; #1 [14]; and #46 [15]), but electron
microscopy showed a variety of abnormalities. Mito-
chondria were either normal (#2 [19]) or had breaks
in their outer membranes (G1 [17]), or elongated (G2
[17]) or abnormal (#1 [14]) shapes. Smooth endoplas-
mic reticulum was increased in amount (G1 [17]; #2
[19]; and #46 [15]); rough endoplasmic reticulum, de-
creased (G1 [17]; #46 [15]). Increased pericellular col-
lagen fibers were present in the space of Disse (G1;
G2 [17]; and #46 [15]), and residual pigment in lyso-
somes of two patient (G3; G4 [17]). Together, these
findings raise concern about liver function in MAT I/
III-deficient patients. To date hepatocellular carcin-
oma has not been found in any of the patients under
discussion. Although most are still relatively young, at
last report patient #2 was 60, four patients were ages
32 to 40; and nine were in their twenties. Taken to-
gether with the fact that the liver function tests in
the 30/64 patients so investigated were normal (in-
cluding several (G1, G2, G4, #2, #46) who had hep-
atic electron microscopic changes) (data not shown in
Tables), these results are encouraging with regard to
liver function and the chances of developing hepatic
malignancies.
Pregnancy outcomes
The fact that five of the patients produced eight normal
babies from nine pregnancies is encouraging. However,
one patient had only two normal babies as a result of six
pregnancies. Further experience will be needed to fully
evaluate the effects of maternal MAT I/III-deficiency on
pregnancy.
CNS abnormalities
Of the 64 patients under discussion, 32 have been classi-
fied as not having evidence of CNS abnormalities, whereas
32 have been classified as having such evidence. It should
be noted, however, that whether a given patient is assigned
to the group of those without or with CNS problems is
subject to several limitations: (a) several of the patients
without evidence of CNS abnormalities are, as yet, very
young (see Table 1 and Fig. 2). CNS problems may arise as
they age. (b) The classification is based most often upon
the reported presence of MRI abnormalities, and there
may be some ascertainment bias with regard to carrying
out MRI studies. Although the majority of patients in both
groups were ascertained by screening of newborns or fam-
ily members (31/32 and 27/32, respectively), among those
without evidence of CNS abnormalities MRI’s were done
on only 6/32 and were in all cases normal, whereas
among those classified as having CNS abnormalities
28/32 had MRI studies with 4 being normal. In the rest
24 being abnormal, 5 became normal and 2 reported as
improving. Thus it is possible that had more of the group
without evidence of CNS abnormalities had MRI’s, more
abnormalities would have been found. (c) The grounds for
classifying a few of the patients as having CNS abnormal-
ities may be weak or not even causally related to MAT I/
III deficiency. The most questionable cases are patient 5
who was considered slow at learning and had Wechsler
Intelligence Scale scores of verbal 86 and performance
84; patient 13 who was slow at school: and, perhaps,
patient 9 who had an IQ of 65 (1st percentile). In spite
of these limitations, as already mentioned in the “Re-
sults” section, the scatter diagram of patients with and
without CNS abnormalities against their mean plasma
methionines (Fig. 2) suggests stratification: those with-
out CNS problems usually have methionines below
800 μM; those with CNS problems have plasma methi-
onines of 800 to almost 1500 μM.
Has dietary methionine restriction, the treatment most
often used, been harmful?
There is concern that, if some residual MAT I/III activ-
ity is still present, lowering methionine concentrations
might further limit the flux due to that residual activity,
as well as the flux through MAT II, thereby further de-
creasing the availability of AdoMet and aggravating the
possibility of developing CNS problems [50]. The present
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Table 4 Histories of patient with possible abnormal CNS
findings
Patient 1: At age 24 y, patient 1 had normal intelligence and no signs of
neurological abnormalities. However, in an MRI at 20 y, signal from
gray substance appeared well differentiated in first “echo” from the
T2 sequences, but was inverted in the second echo, principally in
peripheral regions. There was also a heterogeneous hyposignal from
the posterior part of the central gray nuclei.
4: At age 11 y patient 4 attended normal school, but developed
severe headaches. Nystagmus, dysdiadochokinesis and increased tendon
reflexes were found. An MRI showed delayed myelination in all but the
internal capsule and brainstem. On AdoMet supplementation symptoms
and signs completely resolved and MRI showed restoration of normal
myelination
Patient 5: At age 14 y this patient was considered slow relative to the
rest of her family and to have learning disability. At age 7.5 years she
had, on the Wechsler Intelligence Scale for Children-Revised, a verbal
score of 88 and a performance score of 84. An MRI at age 13 y was
normal, including normal myelination.
Patient 7: Patient 7 was on methionine restriction between 1 month
and 4 months, and again from 6 months to 9 months. An MRI at that
time was normal and a normal diet was restarted. Early gross motor
milestones were delayed. Although neurologically normal at age 4 y, an
MRI showed diffusely abnormal white matter and patchy basal ganglia
bilaterally and abnormally high signal in the inferior aspect and inferior
midbrain. At age 7 y the boy was in special class with memory and
learning disabilities. MRI was stable at age 14 y. A short trial of AdoMet
was stopped by the family because they did not notice improvement in
clinical status. At age 17.8 years there was notable impaired function
and a fine tremor.
Patient 8: At age 7 y this girl had tremor and increased tone in her right
arm with dystonia and dysmetria. An MRI at 9 y showed decreased T1
signal and increased proton density in the left posterior putamen abutting
the posterior limb of the internal capsule. At age 11 y, myelination was
arrested to about 1½ year level.
Patient 9: At age 6 y patient 9 had learning disability. On a Stanford-Binet
Intelligence test he scored 65 (1st percentile), but an MRI was entirely
normal.
Patient 13: An MRI of this girl at 8 y showed patchy alterations of white
matter. At age 16 she required extra time to complete high-school tasks
and was given an “Individualized Education Program”.
Patient 20: An MRI at age 10 y showed white matter changes.
Patient 22: At age 2.8 y patient 22 had febrile seizures with clonic jerks
of the right arm and bilateral clonic seizures. An MRI showed myelination
arrest in the central white matter, putamen, and globus pallidus. An MRI at
4.7 y showed delayed myelination, and supplemental AdoMet was started.
At age 5.4 y her score on an intelligence test improved to 69. An MRI at
6.4 y showed normal myelination.
Patient 29: As early as age 2 y this boy was suspected to have mild mental
retardation. At age 12 y he started to have concentration difficulties
in school and his performance worsened. At age 13 y full scale IQ
was 73 (3.6 percentile) and an MRI showed normal gray-white matter
differentiation in T1 weighted sequence and overall mild hyperintensity
of the subcortical white matter in T2 weighted sequence, suspicious of
hypomyelinization.
Patient 30: From age 3 weeks patient 30 was on dietary methionine
restriction and betaine supplementation. He was neurologically
unremarkable with an IQ of 121 at age 3.5 y, but an MRI at 3.8 y
showed diffuse T1 and T2 prolongation in the subcortical areas
extending to deep white matter, with relative sparing of the corticospinal
tracts, corpus callosum, optic radiations, ventral brain stem, and cerebellar
white matter. There were symmetric lesions in the dorsal brain stem from
the red nucleus to the olivary nucleus areas. Methionine restriction
and betaine were discontinued at age 4 y, and at age 5 y MRI findings
improved, although patchy foci of T1 and T2 shortening were still
Table 4 Histories of patient with possible abnormal CNS
findings (Continued)
observed in the white matter [37]. At age 7 y the delay of myelination
had disappeared [41].
Patient 31: This sib of #30 was on dietary methionine restriction from
age 3 months to 1.8 years. An MRI at 0.8 y showed delayed myelination of
white matter with T1 and T2 prolongation in the symmetric tegmental
tract. At 3 y his development was normal and neurological examination
unremarkable, but MRI showed delayed myelination in white matter with
symmetric lesions in the dorsal brain stem [41].
Patient 32: Patient 32 was on methionine restriction from an early age.
An MRI at 5 y showed delayed myelination equivalent to that in normal
children’s at age 6 months. Methionine restriction was discontinued. An
MRI at age 5.5 y was unchanged [36]. At age 9.4 y his IQ was 108, physical
and neurological examinations were normal, but myelination was the
same as that at 5.5 y.
Patient 34: This child of consanguineous parents had a large head, facial
dysmorphia, severely retarded, slow and infrequent movements of the
body, head and eyes with suspected central visual impairment. After
start of methionine restriction and AdoMet supplementation at about
5.5 months of age, he was said by age 8.3 months to have improved,
but details are not available.
Patient 35: An MRI, performed at age at 1.2 y because MAT I/III deficiency
with severe hypermethioninemia had been established, showed bilaterally
symmetrical restricted diffusion in the commissural fibers of the corpus
callosum, anterior commissure, internal capsule, and globus pallidus.
Spectroscopy demonstrated a diminished NAA peak. MRI at 1.8 y after
6 months of AdoMet administration, showed improvement in areas of
restricted diffusion in the corpus callosum, anterior commissure, globi
pallid, and white matter. The right anterior commissure was the only
area where restricted diffusion was possibly slightly increased.
Patient 36. This identical twin of patient 37, was born prematurely at
32 weeks gestation. At age 2.3 y each twin had developmental delays,
especially of speech, but an MRI of brain of one twin was normal.
Patient 37: See identical twin, patient 36.
Patient 38: This daughter of consanguineous parents and sib of patient
39 was noted at age 3 y to have developmental delay. At age 5 y she
had myoclonic epilepsy treated with valproic acid. At age 11.1 y she was
perfectly healthy apart from learning difficulties for which she was in a
special class at grade 2 level. At age 12.8 y she was in 4th grade rather
than 7th. An MRI showed prolonged relaxation time and shortened
apparent diffusion coefficient
Patient 39: An MRI at 5.2 y showed: prolonged relaxation time, and
2shortened apparent diffusion coefficient in this boy. At age 10.5 years he
was in 3rd grade rather than 5th, but otherwise well.
Patient 41: An MRI at 0.24 y showed: abnormal symmetric T2
hyperintensity along the cortical spinal tract from the perirolandic
white matter through the centrum semiovale, post limb internal
capsule, cerebral peduncles, anterior pons and medulla. Also present
were symmetric abnormal signal within the dorsal brainstem tegmental
tract, extending into the cerebellum and along the hippocampal
formations and within the fornix. Within these areas there was restricted
diffusion and diffuse swelling. The patient was started on methionine
restriction which has continued to present. AdoMet supplementation
was started at age 6.7 y. An MRI at 7.1 y was normal and the parents
think AdoMet has been very helpful.
Patient 42: An MRI of this boy at 1.2 y showed bilateral symmetrical
areas of hyperintense T2-weighted images in white matter at the level of
temporal-insular and temporal-mesial, deep parietal, ponto-mesencephalic,
dorsal and cerebral peduncles with involvement of the structures
above and the capsular lenticular corpus callosum. ADC values were
reduced to diffusion. At age 1.5 y he was noted to have speech delay.
Patient 43: This boy was on methionine restriction from age 0.8–3.2 y.
At 3.3 y a neuropsychological evaluation found a developmental age of
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study produced results for eight patients, each of whom
has had some period of methionine restriction, who
remained free of evidence of CNS abnormalities (see first
section of Table 3). Five of these had only missense muta-
tions; patient 48 had one missense and one truncating
mutation; patient 58 was not sequenced. The methionine
restriction used for these individuals did no apparent
harm. Patient 13 is one in whom restriction may possibly
have had adverse effects. Although his methionine on nor-
mal diets at ages was 485 μM, after methionine restriction
from age 1.7 to 10 months with a mean level of 193 μM
he was found at age 8 to have an abnormal MRI and was
judged to be slow at school.
Has methionine restriction been beneficial?
Evidence as to the usefulness of methionine restriction is
limited and prevents drawing any firm conclusions.
Findings that might be considered strongly convincing
of benefit would be for example an individual with me-
thionine values of > 900 μM at ≥ 5 months on normal di-
ets, who after using a methionine restricted diet remained
free of CNS abnormalities, but such informative cases are
not available. For the eight patients without evidence of
CNS abnormalities who had been on dietary restriction
(Table 3), mean methionine values on normal diets at
ages ≥ 5 months ranged from 175 to 777 μM (mean
388 ± 208), so there is a likelihood that they would not
have had CNS abnormalities even if they had not been
on methionine restriction. The findings for several pa-
tients, however, are at least suggestive of benefit: pa-
tient 20 remained normal until age 5.4 years while on
methionine restriction that kept his methionine down
to 684 μM, but developed MRI abnormalities after diet
was discontinued and methionine climbed to 1298 μM.
Patient 1 (during) and patient 46 (after) methionine re-
striction are normally intelligent at ages 20.7 and 34 years,
although each has MRI abnormalities. Patient 13 devel-
oped abnormalities after stopping methionine restriction.
Patient 62’s behavior improved on restriction and patient
63’s MRI worsened after stopping restriction.
Pathophysiology
As just detailed, judged by the data on outcomes, the
evidence available as to optimal treatment of the patients
in question is unclear. An alternative means to try to
find the optimal treatment might be to consider the
pathophysiology of the metabolic abnormalities in MAT
I/III deficiency. There is strong evidence of stratification
between the presence or absence of CNS problems and
mean methionine concentrations. This could indicate
toxicity of very high methionine concentrations itself,
deficiency of AdoMet due to more severe loss of MAT
I/III activity, the rises in tHcy, or some combination of
more than one of these factors. Details of each of these
alternatives are discussed below.
Table 4 Histories of patient with possible abnormal CNS
findings (Continued)
27 months and IQ’s of 78 on performance and 57 on reasoning. The
diet was restarted. An MRI at 3.8 y showed delayed myelination peripherally
throughout. On FLAIR examination there were multiple periventricular
focal white matter hyperintensities.
Patient 45: At age 4 y physical and neurological examinations and
physiotherapeutic testing of patient 45 were normal, but an MRI
showed white matter changes and delayed myelination. At age 4.1
y she started protein restriction and supplemental AdoMet. At age
4.5 y physical and neurological examinations and physiotherapeutic
testing continued to be normal. An MRI showed normal white matter and
delayed myelination.
Patient 46: This woman was on methionine restriction from age 0.1–4.0 y,
then on a normal diet. Her IQ by WISC-R at age 9 y was 99 [15, 46]. An MRI
at age 30 y showed T1 and T2 prolongation in the deep white matter, but
physical and mental development have been entirely normal.
Patient 47: A dietary history is not available for this patient. At age 9 y she
had dysdiadochokinesia and MRI showed hypomyelination. At age 10 she
had normal cognition and an MRI at age 17 y was almost normal.
Patient 50: An MRI of patient 50 at 4.3 y showed: white matter changes,
in particular restricted diffusion in the area of the genu of the corpus
callosum. There were no changes in T1 or T2. Supplementation with
AdoMet, 200 mg/d was started at age 4.4 y and the dose increased to
400 mg/d at 4.5 y. The patient’s behavior with regard to aggression and
hyperactivity were improved at 4.9 y.
Patient 51: The behavior of this younger sister of patient 50 deteriorated
by age 3.7 y and supplementation with AdoMet was started at 200 mg/d.
Outcome not know to date.
Patient 56: This woman was ascertained and genotyped at age 38
y as a result of having given birth to two children with transient
hypermethioninemia on newborn screening. She had never been
on methionine restriction. She received average grades throughout
school and has an associate degree. She has had hand tremors since
childhood and is affected with depression. Physical examination
showed increased deep tendon reflexes, tremors, dysmetria and
dysdiadochokinesis.
Patient 60: Despite her normal development until age 1.4 y, an MRI
showed extensive abnormal signal in the white matter of the corpus
callosum and of the anterior commissure. Neuroimaging at age 2 years
showed similar results [40]. At age 5.6 years she showed possible mild
neuropsychotic delay and hyperreflexia.
Patient 61: At early age (3 weeks) this boy was treated with methionine
restriction and betaine because of mild hyperhomocysteinemia. At age
2.5 years pyridoxine was added. Treatment was discontinued at age 3.9
years. Brain demyelination was revealed at age 3.5 years and confirmed
at 4.5 years. At age 5.5 no neurological symptoms were reported.
Patient 62: At age 2.1 years developmental delay and autistic action of
this boy led to the start of dietary methionine restriction. An MRI at age
2.3 y was normal and the diet was discontinued at age 2.4 y. IQ is 108
at age 3.3 y. At age 4.3 y the boy was developing normally and
attending kindergarten.
Patient 63: At age 10 months an MRI of patient 63 showed diffuse abnormal
lesions in the white matter indicative of delayed myelination. T2-weighted
images showed no myelination in the external capsules or anterior
limbs of the internal capsules, but lack of T1-weighted images made
evaluation difficult. At 18 months the abnormal lesions in the white
matter were more extensive. However, at age 2.9 y, there were no
neurological signs.
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Fig 2 Plasma methionine concentrations for patients on normal diets without (green) or with (red) evidence of CNS abnormalities. Green values
are plotted against age at last report; red values, against age at which CNS abnormality was first found. Triangles indicate mean methionine
values at ages≥ 5 months; circles indicate mean methionine values at ages < 5 months (if values at older ages are not available; and plotted
against age at last report)
Fig. 1 Mean plasma methionine values of untreated patients in the first months of life are plotted against mean ages at which samples were
drawn. Red markers indicate patients with evidence of CNS abnormalities; green markers, patients without such evidence
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Methionine elevation
High plasma methionine and brain edema
The MAT I/III deficient patient of Tada et al. (#30) de-
veloped brain edema while on betaine (and B6) treat-
ment resulting in methionine concentrations between
960 and 1560 μM [36]. Braverman et al. [52] reviewed
four cases with edema and severe elevations of plasma
methionine. Brain edema developed in two CBS defi-
cient patients on betaine with methionine of 1190 and
3000 μM. Because betaine is also an intracellular osmo-
lyte, its high levels may have contributed to the devel-
opment of edema. In the same report Braverman et al.
reviewed two normal infants having edema after an ex-
treme high methionine intake resulting in plasma me-
thionines of 2154 and 6830 μM.
Taken together very severe elevations of methionine
(above 2000 μM) may induce edema, whereas the use of
betaine may already lead to edema if plasma methionine
is above 1000 μM. Although edema is only reported in
patients with MAT I/III deficiency if using betaine, it
can not be ruled out that a more subtle inability of cells to
pump water adequately may contribute to CNS problems.
Might methionine inhibit some methyltransferase activity
necessary for myelination or another vital CNS function?
Methyl transfer reactions definitely occur in brain [56],
but their quantitative extent has not been established.
A review of the literature turned up no instances of
methionine inhibition of an AdoMet-dependent methyl
transfer reaction.
Might some break-down product of methionine play a role
in CNS problems?
Dever and Elfarra [57] pointed out that products of the
methionine transamination pathway and/or sulfoxidation
should be considered as a potential cause of CNS prob-
lems. It is well established that patients with methionine
elevations now known to be due to MAT I/III deficiency
utilize transamination when plasma methionine is above
about 350 μM [58]. Evidence on transamination or
Fig. 3 Plasma AdoMet as a function of plasma methionine. Symbols are the same as those used in Fig. 2. For each patient the mean plasma
methionine concentration on normal diets at ages≥ 5 months is plotted against the mean plasma AdoMet concentration on normal diets at
ages≥ 5 months. Patients without and with evidence of CNS abnormalities are shown, respectively, by red or green markers
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sulfoxidation products has not been collected during the
present survey. We do know that Patient 2, a homozy-
gote for a truncating mutation, presented with bad
breath odor due to dimethylsulfide formed by the trans-
amination pathway [20], but that he remains clinically well
at age 60 years. Another argument against the transamin-
ation and/or sulfoxidation products hypothesis is that it
would not explain the beneficial effect of AdoMet sup-
plementation, for which there is relatively strong evi-
dence (as mentioned in sections 5.1.5 and 5.2.1).
Might very high methionine compete for transport of other
amino acids across the blood–brain-barrier so severely as
to cause damage?
Methionine is transported across the blood–brain-bar-
rier by the “large neutral amino acid” (LNAA) system, as
are nine other amino acids. Phenylalanine has the lowest
Km, 11 μM, for this system; methionine is the fourth
lowest, 40 μM [59]. The system normally functions near
saturation with LNAA’s, so that if one of them rises
above its normal plasma level, to some extent, it will
compete with the other LNAA’s and inhibit their trans-
port across the blood–brain-barrier [59]. One hypothesis
to explain the CNS damage of phenylketonuria (PKU) is
that competition by phenylalanine for LNAA transport
accounts for the adverse effects [60]. Until recently there
was an international consensus that phenylalanine levels
of < 360 μM are not harmful and do not need treatment.
More recent evidence has shown that even phenylalan-
ine levels of as high as 800 μM are either clinically be-
nign [61], or lead only to MRI changes of uncertain
significance [62]. Because the Km of methionine for the
LNAA transporter is 40/11 = 3.6-fold higher than that of
phenylalanine, it seems that the extent of competitive in-
hibition of LNAA uptake by methionine concentrations
of as much as 3.6 × 360 μM= 1296 μM are unlikely to
Fig. 4 Values for plasma methionine and tHcy are plotted for individual samples from patients on normal diets. Red and green triangles and circles
are used as in Fig. 2 to indicate either presence or absence of CNS abnormalities and ages either above or below 5 months
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be harmful, whereas concentrations above 1296 μM and up
to 3.6 × 800 = 2880 μMmight bring about MRI changes.
Might high plasma methionine inhibit the transport of
AdoMet into brain?
Chishty et al. describe the carrier mediated transport of
AdoMet to the blood–brain barrier by system(s) that
transport adenosine, but not methionine [63]. Therefore,
it seems unlikely that methionine interferes with trans-
port of AdoMet across the blood–brain barrier. CSF
AdoMet concentrations without AdoMet supplementa-
tion are available for three patients, each of whom had
CNS problems: two, patient 4 [64] and patient 29 [44],
had somewhat low levels; one (patient 43) had a normal
level. It is noteworthy that the concentration of AdoMet
in CSF may not accurately reflect the brain tissue con-
centration. For example, there was no significant rela-
tionship between AdoMet concentrations in CSF and
those in brain after treatment of pigs with nitrous oxide
which dramatically changed the AdoMet/AdoHcy ratio
[65]. Metz also discussed this discrepancy in his review
article [66]. In spite of these limitations, it appears that
there is no strong evidence that high plasma methionine
interferes with delivery of AdoMet from plasma to brain.
Might very high methionine somehow decrease the AdoMet
concentration of the brain?
One possibility is that methionine inhibits MAT II activ-
ity. However, studies of the kinetic properties of MAT II
do not mention methionine inhibition of this activity
[67], even when brain MAT II was studied [68]. Another
possibility is that high methionine might lead to de-
creases in the amount, rather than the activity, of MAT
II. Such an effect has been reported in both human
hepatoma [69] and neuroblastoma cells [70], but not in
H35 or cos7 cells [71]. However the effect in hepatoma
cells depended upon synthesis of AdoMet, so it seems
unlikely to occur in brain in cases of MAT I/III defi-
ciency. Direct evidence of the effect of high methionine
on brain AdoMet concentrations has been reported by
Young and Shalchi, who assayed AdoMet in rat brains
after administration of increasing doses of methionine
and found a tendency for brain AdoMet concentrations
to decrease with the higher doses of methionine [72]. If
the brain AdoMet levels in the MAT I/III-deficient pa-
tients follow the tendency reported by Young and Shalchi
to decrease in the presence of especially high methionine,
and fall below normal with the highest plasma methio-
nines (a proposition that needs to be tested, at least on ex-
perimental animals) it would then be plausible to suggest
that the CNS problems of MAT I/III deficiency with the
higher elevations of methionine are due in part to lack of
AdoMet. Such a suggestion, if correct, would provide not
only an explanation of the CNS pathology, but also indi-
cate why supplementation with AdoMet might be helpful.
MAT I/III activity
Is there a relationship between the severity of loss of MAT I/III
activity and the presence of CNS problems?
No such relationship is clearly established. Determin-
ation of the MAT1A genotype for a given patient does
not provide a firm basis on which to judge the likelihood
of CNS damage. A patient homozygous for truncating
mutations that presumably leave no residual MAT I/III
activity do not have CNS problems (e.g., Patient #2).
Several compound heterozygotes with mutations that,
when expressed individually in E. coli, have at least some
residual activities [25–27, 34] do have CNS problems
(e.g., patients 5, 9, 13, 20, 30, 31, 36, 37, 38, 39, 46, 60).
One possibility is that more severe loss of MAT I/III ac-
tivity and the resulting decrease in the rate of synthesis
of AdoMet might lead to lowering the level of plasma
AdoMet, thereby decreasing delivery of AdoMet from
plasma to brain. However Fig. 3 shows that there is no
trend for those with higher plasma methionines to have
lower plasma AdoMet concentrations. Presumably plasma
AdoMet is sustained at normal (93 ± 16 nM) or close to
normal by MAT II activity even when MAT I/III activity
is low or negligible (note that MAT II expression and pro-
tein are increased three-fold in MAT1A KO mice [54]).
Figure 3 provides strong evidence that the CNS damage is
not the result of differential delivery from plasma to brain
at the concentrations that occur without AdoMet supple-
mentation. It does not rule out the possibility that at
higher concentrations of AdoMet resulting from supple-
mentation, there might still be a therapeutic increase in
the delivery of AdoMet to brain. Orally administered Ado-
Met has been shown to raise the plasma [73, 74] and the
CSF [74] concentration of AdoMet. Because in most cases
AdoMet supplementation has had positive therapeutic ef-
fects (Table 3), this method of therapy is supported by the
available evidence.
Does loss of hepatic MAT I/III activity impair the
synthesis, and subsequent delivery from liver to brain of
one or more compound(s) important in CNS function?
This possibility was considered previously for creatine
and choline, formed in liver by the AdoMet-dependent
guanidinoacetate and phosphatidylethanolamine methyl-
transferases [75], and appeared to be supported when
early genetic studies found that two patients with brain
demyelination were homozygotes for truncating MAT1A
mutations that led to complete loss of MAT I/III ac-
tivity [26]. However, the subsequent finding of a
homozygous MAT1A mutation in a clinically well older
patient (Patient #2) weakened the hypothesis in ques-
tion and the data in Table 1 showing a lack of correlation
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between complete loss of activity and CNS problems fur-
ther weaken it.
Another possibility related to decreased flux through
phosphatidylethanolamine methyltransferase is that such
decreases lead to CNS damage that may be prevented by
docosahexaenoic acid (DHA) [76], a compound important
in normal brain development and one the dietary intake
of which is highly variable [77]. The intakes of DHA, and/
or sources of choline, and creatine at crucial periods dur-
ing growth, may therefore have played roles in the pres-
ence or absence of CNS problems in the MAT I/III
patients. Variability in the CNS status of the three patients
homozygous for R199C (patients 10, 11, and 13) might
possibly be an example of effects of such factors (see, also
the discussion [78]).
Does MAT I/III activity in brain contribute so significantly to
the CNS need for AdoMet that more severe losses lead to
the CNS problems?
Reytor et al. have shown that MAT1A is expressed in
brain [12] but the expression in brain is very low (per-
haps 0.2 %) of that in liver. It remains unclear what the
total requirement of brain for AdoMet is, or the extent
to which that requirement is met by MAT II. There is
also the possibility that expressed MAT1A product af-
fects nuclear localization or plays a role in, for example,
specialized histone methylations [12], so a definitive an-
swer to the question of the role of MAT1A expression in
brain is not available.
Do the increased levels of tHcy lead to the CNS problem?
As shown in Fig. 4, and consistent with previous obser-
vations [49], tHcy tends to rise as methionine increases.
However, there is no striking elevation of the tHcy
values for those with CNS problems above the tHcy
values for those without CNS problems. Furthermore
the tHcy levels are not higher than the values found in
treated cystathionine β-synthase (CBS) deficient pa-
tients who have essentially normal IQ’s [79].
Summary conclusions and tentative suggestions
for management
No definitive answer to the question of what is the best
strategy for management of severe MAT I/III deficiency
emerges from consideration of either the available evi-
dence on treatment outcomes or the numerous patho-
physiologic mechanisms through which either loss of
MAT I/III activity, methionine elevation, or some com-
bination of both might lead to CNS problems. Given these
givens, we suggest here what seem at this time to be rea-
sonable, although tentative, management guidelines:
In an asymptomatic, well looking newborn of normal
birthweight and gestational age with persistent hyper-
methioninemia and plasma tHcy higher than, perhaps
100 μM, CBS deficiency becomes the presumptive diag-
nosis. If, at most, plasma tHcy is elevated to perhaps
50–60 μM, the diagnosis is less clear. Determining the
concentrations of AdoMet and AdoHcy in plasma of the
patient, and, if possible, methionine in both parents will
further pin-point the defect. To rule out CBS deficiency
one may also determine cystathionine but this requires
a suitably sensitive assay available in only a few special-
ized laboratories” [51]. Determination of the CBS activ-
ity in cultured fibroblasts and sequencing of the CBS
gene will provide a final diagnosis. In the differential
diagnosis of hypermethioninemia also deficiencies of S-
adenosylhomocysteine hydrolase, adenosine kinase and
glycine N-methyltransferase need to be mentioned. These
inborn errors of methionine metabolism may also show
elevated tHcy. The determination of AdoMet and AdoHcy
is most helpful in pinpointing the potential defect.
Secondary causes of hypermethioninemia include liver dis-
ease, tyrosinemia type I, galactosemia and citrin deficiency.
The majority of newborns now being flagged for me-
thionine elevations in screening programs with lowered
methionine cut-off values are turning out to be heterozy-
gotes for one of the MAT1A mutations now known to
cause mild to moderate hypermethioninemia. This hetero-
zygosity will almost surely cause no adverse long-range
clinical effects. If neither parent has a mild methionine
elevation, and a sample up to three months has no more
than a slightly high concentration of AdoMet at a time the
methionine remains high, a diagnosis of homozygous or
compound heterozygous MAT I/III deficiency is strongly
indicated. Sequencing of the MAT1A gene will help to
make the diagnosis more specific and secure. While these
steps are being taken, the newborn might be monitored by
assay of plasma methionine at about 1 month intervals. If
that mean is above perhaps 500–600 μM, dietary methio-
nine restriction should be considered, strict enough to
maintain a methionine concentration near that level, but
not a great deal below it. In patients with Mudd’s disease
methionine levels may vary wide in the first months of life
making the decision on methionine restriction not
straightforward in this period. If possible this decision can
better be made after the first months of life. If the mean
plasma methionine is below 500 μM it seems likely that
dietary restriction is not indicated.
Whether on methionine restriction or not, an eye
should be kept out for development of CNS abnormal-
ities and, if indicated, brain MRI performed. If prob-
lems arise while on a normal diet, starting or restarting
methionine restriction or AdoMet supplementation
may be considered. If problems develop while on re-
striction, supplementation with AdoMet should be con-
sidered. The available evidence suggests that AdoMet
supplementation may lead to normalization of even
MRI changes that have already occurred.
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It is important to emphasize, again, that the stratifica-
tion into those with or without evidence of CNS abnor-
malities, upon which the above suggestions rely to provide
guidance, may be affected by ascertainment bias, and that
the management guidelines put forth here are tentative
and will need to be reevaluated and perhaps modified as
experience with MAT I/III deficiency is extended.
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